source
- FDA greenlights Takeda and Protagonist's rusfertide (Mimrylo) for polycythemia veraThe U.S. Food and Drug Administration has granted approval to rusfertide, a therapy developed jointly by Takeda Pharmaceutical and Protagonist Therapeutics. The drug, to be marketed under the name…
- BioNTech and Genentech halt Phase 2 trial of personalized mRNA cancer vaccineBioNTech and its partner Genentech announced the termination of a Phase 2 study evaluating a personalized mRNA cancer vaccine. The decision was made shortly after the trial had entered its second s…